NEW YORK, NY / ACCESSWIRE / July 10, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting Click Here
NEW YORK CITY, NY / ACCESSWIRE / July 10, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
NEW YORK, NY / ACCESSWIRE / July 9, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting Click Here
NEW YORK, NY / ACCESSWIRE / July 8, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting Click Here
NEW YORK, NY / ACCESSWIRE / July 7, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting Click Here
SAN FRANCISCO, CA / ACCESSWIRE / July 6, 2024 / Hagens Berman urges Elanco Animal Health Incorporated (NYSE: ELAN) investors who suffered substantial losses to submit your losses now. Visit: www.hbsslaw.com/investor-fraud/elan Contact the Firm Now: [email protected] 844-916-0895 Investigation into Elanco Animal Health Incorporated (ELAN): Elanco Animal Health is facing questions from investors regarding the accuracy of its previous statements concerning the commercial launch timelines for two key products.
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Elanco Animal Health Incorporated ("Elanco") (NYSE:ELAN) concerning possible violations of federal securities laws. Elanco issued a press release on June 27, 2024, "announc[ing] updates to the expected U.S. Food and Drug Administration (FDA) approval timelines for Zenrelia and Credelio Quattro.
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting Click Here
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Elanco Animal Health Incorporated ("Elanco") (NYSE:ELAN) concerning possible violations of federal securities laws. Elanco issued a press release on June 27, 2024, "announc[ing] updates to the expected U.S. Food and Drug Administration (FDA) approval timelines for Zenrelia and Credelio Quattro.
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Elanco Animal Health Incorporated ("Elanco") (NYSE:ELAN) concerning possible violations of federal securities laws. Elanco issued a press release on June 27, 2024, "announc[ing] updates to the expected U.S. Food and Drug Administration (FDA) approval timelines for Zenrelia and Credelio Quattro.
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Elanco Animal Health Incorporated ("Elanco" or the "Company") (NYSE:ELAN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / July 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Elanco Animal Health Incorporated ("Elanco") (NYSE:ELAN) concerning possible violations of federal securities laws. Elanco issued a press release on June 27, 2024, "announc[ing] updates to the expected U.S. Food and Drug Administration (FDA) approval timelines for Zenrelia and Credelio Quattro.